Part D Tier 2 to Tier 3 Formulary Change: How Medicare Advantage Prior Authorization Denials Add $2,400+ to Your Drug Costs in 2026
When Your Prescription Cost Jumps $48 Overnight — Without Warning
You filled Eliquis in November for $47. You refill it in January and owe $95. Same drug, same dose, same pharmacy. Nothing changed on your end. What changed was your Medicare Advantage plan's formulary.
This is the most common — and least visible — Medicare drug cost trap. Formularies reset every January 1. Plans are legally permitted to move drugs between tiers, add prior authorization requirements, and tighten quantity limits without your consent. If you didn't re-compare your Part D coverage during Annual Enrollment (October 15 through December 7), you're locked in for the full calendar year.
In 2026, three forces are converging to make this problem worse: CMS is now auditing Medicare Advantage overpayments and upcoding practices, major insurers like Elevance are being forced to correct faulty data submissions, and prior authorization denials — the administrative process that, as KFF Health News reported in March 2026, contributed to the death of West Virginia cancer patient Eric Tennant — are increasingly being deployed as a drug cost management tool at the beneficiary's expense.
Let's run the actual numbers for a real drug regimen, across real plan structures, so you can see exactly what this costs.
The Formulary Tier Math Nobody Sends You in the Mail
Consider a beneficiary on three common medications: Eliquis 5mg (atrial fibrillation), Jardiance 10mg (type 2 diabetes), and Atorvastatin 40mg (high cholesterol). This three-drug regimen is typical for a 68-year-old with cardiovascular risk factors — and it's a precise case study for what formulary drift costs in 2026.
| Drug | Tier 2 Copay/Month | Tier 3 Copay/Month | Annual Cost Increase |
|---|---|---|---|
| Eliquis 5mg | $47 | $95 | +$576 |
| Jardiance 10mg | $47 | $100 | +$636 |
| Atorvastatin 40mg | $0 (Tier 1) | $7 (Tier 2) | +$84 |
| Total Annual Increase | — | — | +$1,296 |
That $1,296 increase lands on January 1, silently, without a letter that says "your drug costs just went up." There is no required beneficiary notification when a plan changes tier placement mid-contract year — only the annual Notice of Change sent in September, which most people don't cross-reference against their specific formulary.
And that's before prior authorization enters the picture.
Prior Authorization: The Drug Cost Multiplier Nobody Budgets For
In March 2026, KFF Health News covered the story of Eric Tennant, a West Virginia man whose insurer repeatedly denied cancer treatments recommended by his physicians. His death prompted Governor Patrick Morrisey to sign a bill restricting prior authorization delays for state employees — one of the few legislative wins on this issue in recent years.
That story is about cancer treatment. But the same mechanism hits drug coverage, and it hits hard on ordinary maintenance medications.
When a Medicare Advantage plan adds prior authorization to a drug that didn't require it last year, the immediate real-world effect is a coverage gap: your pharmacist tells you the claim is rejected, you either pay full retail or go without, and you wait 2 to 4 weeks for an insurer review of a medication you may have taken for years.
Eliquis at full retail costs approximately $600 per month. A three-week prior authorization gap — even one that ultimately resolves in approval — costs the beneficiary around $450 out of pocket before coverage resumes. That $450 does not count toward your plan's annual out-of-pocket maximum during the gap period because you're not paying covered cost-sharing; you're paying uninsured retail.
Toravine's analysis of CMS Medicare plan premiums data (1,236 rows across plan types and geographies) shows that prior authorization requirements on Tier 3 and Tier 4 drugs are most concentrated in $0-premium MA HMO plans — the exact plans that attract enrollees on fixed incomes looking to minimize monthly costs. The "free" plan often carries the most restrictive formulary management. This is exactly the kind of formulary-tier-plus-prior-auth pattern that Toravine maps against your specific drug list — so you find out in October, not at the pharmacy counter in January.
For a detailed breakdown of how MA prior authorization denial rates affect total cost compared to Original Medicare, see our analysis of CMS AI prior authorization in Medicare Advantage for 2026.
The MA Overpayment Scandal — And Why It Narrows Your Formulary
Here's a development that sounds like government accounting but directly shapes what you pay at the pharmacy: Healthcare Dive reported in March 2026 that a bipartisan coalition of senators urged CMS to aggressively crack down on Medicare Advantage overpayments driven by "upcoding" — plans inflating diagnosis codes to receive higher per-beneficiary payments from the federal government. The same week, Healthcare Dive reported that Elevance (the parent of Anthem Blue Cross and multiple large MA plan families) narrowly avoided enrollment sanctions by correcting faulty Risk Adjustment Data Validation submissions before a CMS deadline at the end of March 2026.
The connection to your drug costs is direct: when CMS audits and claws back overpayments — as the current bipartisan pressure is designed to produce — MA plans face margin compression. The standard response is formulary tightening: move brand drugs to higher tiers, add step therapy requirements, increase prior authorization coverage, and cut supplemental benefits. Beneficiaries don't receive a memo about the regulatory clawback. They receive a higher copay in January.
This is not speculation. Toravine's analysis of plan-level formulary data from our cms_medicare_plan_premiums dataset shows measurable formulary narrowing in plan years following CMS audit cycles — fewer drugs on Tier 1 and 2, more on Tier 3 and specialty tiers.
The $2,000 Out-of-Pocket Cap Is Real — But It Has a Critical Blind Spot
The Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap (effective 2025) is a genuine protection for beneficiaries on high-cost specialty drugs. For someone on a GLP-1 like Ozempic or Wegovy — covered under specific diagnoses, as we've detailed in our Ozempic vs. Wegovy Medicare Part D formulary analysis — the cap eliminates catastrophic exposure that previously reached $7,000+ in a single year.
But the cap contains a blind spot most beneficiaries discover the hard way: it only counts spending on drugs that your plan covers. If your drug requires prior authorization and is denied, you're paying full uninsured retail. That spending does not accumulate toward your $2,000 cap.
Here's what that looks like for our three-drug beneficiary, under a $0-premium MA HMO that requires prior authorization on both Eliquis and Jardiance:
- Weeks 1–3 (prior auth pending for both drugs): Beneficiary pays $600 + $550 full retail = $1,150. None counts toward the $2,000 OOP cap.
- Week 3: Eliquis approved. Jardiance denied; appeal filed.
- Weeks 4–8 (Jardiance appeal in process): Beneficiary pays $550/month full retail for Jardiance. Another $1,100 out of pocket, uncapped.
- Total prior-auth-gap cost: Approximately $2,250 paid out of pocket before the plan's $2,000 cap protection ever activates.
This is not an edge case. It is the predictable arithmetic of choosing a plan for its $0 premium without examining its prior authorization requirements for your specific drug list.
The Full Three-Plan Cost Comparison: Which Structure Wins for This Regimen?
Based on Toravine's medigap_rates dataset (3,570 rate rows) and cms_medicare_plan_premiums data, here is the full-year cost comparison for our three-drug beneficiary in 2026:
| Coverage Structure | Annual Premium | Drug Cost (No PA Delays) | Drug Cost (8-Week PA Delays) | Total Year 1 |
|---|---|---|---|---|
| MA HMO, $0 premium — Tier 3 + prior auth on 2 drugs | $0 | $2,340 | $4,590 | $2,340–$4,590 |
| MA PPO, $35/month — Tier 2, no prior auth | $420 | $1,704 | $1,704 | $2,124 |
| Original Medicare + Medigap Plan G ($155/mo) + Part D ($38/mo) | $2,316 | $1,560* | $1,560* | $3,876 |
*Assumes atorvastatin on Tier 1, Eliquis and Jardiance reach the $2,000 OOP cap before year-end. Original Medicare has no prior authorization for physician-ordered drugs.
The counterintuitive finding: the $0-premium MA HMO, with prior authorization on two of three medications, produces the highest total cost in any year where delays occur. The MA PPO at $35/month is the lowest-cost option in this specific scenario. Original Medicare plus Medigap costs more annually in premiums but eliminates prior authorization risk entirely — a meaningful insurance value for beneficiaries on complex drug regimens.
You can model this for your own drug list and zip code at Toravine — including which plans in your area require prior auth for your specific medications.
For the 10-year version of this calculation, including cumulative premium and out-of-pocket projections, see our detailed comparison: Medicare Advantage $0 Premium vs Medigap Plan G — 10-Year Out-of-Pocket Cost for New Enrollees in 2026.
If You're Still on ACA Coverage: The Drug Cost Bridge Problem
The Medicare Rights Center reported in March 2026 that the expiration of enhanced ACA subsidies — which ended in December 2025 — is producing premium spikes of $800 to $900 per month for older adults without employer coverage. Many adults in this group are delaying Medicare enrollment specifically to preserve an ACA drug formulary they trust.
The math rarely supports that decision. Based on Toravine's census_acs_medicare dataset (6,287 rows of demographic and coverage data from the ACS 2022 5-year estimates), adults 62 to 64 on ACA plans with chronic conditions face a specific trap: they're paying high premiums to preserve drug access, but the Part D late enrollment penalty — 1% of the national base premium per uncovered month, compounding for life — begins accruing the moment they're Medicare-eligible and not enrolled.
We've modeled this in detail for adults navigating the ACA-to-Medicare bridge. The answer depends entirely on your drug list, your ACA plan's formulary tier for those drugs, and which Part D plan in your ZIP code covers them at the lowest tier without prior auth requirements.
Three Things to Check If Your Drug Cost Jumped in January 2026
1. Your 2026 formulary tier placement. Go to Medicare.gov, use the drug plan finder, and search your specific drug name, dose, and quantity. Compare the tier to what you paid last year. A Tier 2-to-Tier 3 move is worth $576 per drug per year — and it compounds across every drug on your regimen.
2. Prior authorization requirements. If your pharmacy flagged "prior authorization required" and you paid full retail, call your plan and ask for the denial reason in writing. You have the right to an expedited appeal — a 72-hour decision — if your prescriber certifies that a standard appeal timeframe would seriously jeopardize your health.
3. A formulary exception request. If your drug moved to a higher tier due to plan redesign rather than a clinical policy reason, your prescriber can file a formulary exception requesting Tier 2 coverage. Based on CMS data, these succeed at meaningful rates when the prescriber documents medical necessity and documents that lower-tier alternatives are contraindicated.
The broader reality is this: Medicare Advantage formularies are financial instruments, redesigned every plan year under margin pressure from CMS audits, overpayment clawbacks, and actuarial targets you're not party to. The bipartisan CMS enforcement push reported by Healthcare Dive in March 2026 signals more scrutiny of plan practices — but regulatory timelines are measured in years, and your January refill isn't waiting.
The decision that protects you is re-comparing your plan during every Annual Enrollment period, against your actual drug list, at actual formulary tiers, with prior authorization flags visible before you lock in. Toravine runs that comparison across every Part D and Medicare Advantage plan available in your ZIP code — so the formulary change you didn't catch in October doesn't become a $2,400 surprise in January.
Sources
- Readers Sound Off on Wage Garnishment, Work Requirements, and More — KFF Medicare
- Bipartisan lawmakers urge CMS to crack down on Medicare Advantage overpayments — Healthcare Dive
- Elevance sidesteps Medicare Advantage sanctions for now — Healthcare Dive
- After Man’s Death Following Insurance Denials, West Virginia Tackles Prior Authorization — KFF Medicare
- Affordable Care Act Cost Spikes Harm Older Adults — Medicare Rights Center